ANAVEX 2-73 Could Prevent Alzheimer’s Disease in Addition to Modifying and Treating Symptoms

Pre-clinical Study Demonstrates ANAVEX 2-73’s Ability to Preserve Mitochondrial Integrity and Block the Oxidative Stress and Cell Death that Leads to Amyloid-Beta Overproduction and Tau Hyperphosphorylation NEW YORK, NY – February 25, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a research report in the…